A detailed history of Rhumbline Advisers transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Rhumbline Advisers holds 104,398 shares of COLL stock, worth $3.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
104,398
Previous 108,147 3.47%
Holding current value
$3.36 Million
Previous $3.33 Million 21.75%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

SELL
$31.23 - $40.91 $117,081 - $153,371
-3,749 Reduced 3.47%
104,398 $4.05 Million
Q4 2023

Feb 08, 2024

SELL
$21.16 - $30.8 $38,828 - $56,518
-1,835 Reduced 1.67%
108,147 $3.33 Million
Q3 2023

Nov 09, 2023

BUY
$21.23 - $24.28 $20,975 - $23,988
988 Added 0.91%
109,982 $2.46 Million
Q2 2023

Aug 08, 2023

BUY
$21.06 - $24.0 $137,163 - $156,312
6,513 Added 6.36%
108,994 $2.34 Million
Q1 2023

May 11, 2023

BUY
$23.0 - $29.88 $165,255 - $214,687
7,185 Added 7.54%
102,481 $2.46 Million
Q4 2022

Feb 14, 2023

BUY
$16.14 - $23.55 $3,050 - $4,450
189 Added 0.2%
95,296 $2.21 Million
Q3 2022

Nov 10, 2022

BUY
$15.46 - $20.1 $27,055 - $35,175
1,750 Added 1.87%
95,107 $1.52 Million
Q2 2022

Aug 11, 2022

SELL
$14.22 - $20.88 $40,768 - $59,862
-2,867 Reduced 2.98%
93,357 $1.65 Million
Q1 2022

May 12, 2022

BUY
$17.2 - $22.5 $94,754 - $123,952
5,509 Added 6.07%
96,224 $1.96 Million
Q4 2021

Feb 10, 2022

BUY
$17.5 - $21.35 $20,282 - $24,744
1,159 Added 1.29%
90,715 $1.7 Million
Q3 2021

Nov 12, 2021

SELL
$17.75 - $25.39 $204,036 - $291,858
-11,495 Reduced 11.38%
89,556 $1.77 Million
Q2 2021

Aug 05, 2021

SELL
$21.74 - $25.28 $72,524 - $84,334
-3,336 Reduced 3.2%
101,051 $2.39 Million
Q1 2021

May 06, 2021

BUY
$19.25 - $26.1 $1.09 Million - $1.48 Million
56,692 Added 118.86%
104,387 $2.47 Million
Q4 2020

Feb 10, 2021

SELL
$17.83 - $22.29 $1,444 - $1,805
-81 Reduced 0.17%
47,695 $955,000
Q3 2020

Nov 12, 2020

SELL
$15.78 - $20.82 $134,492 - $177,448
-8,523 Reduced 15.14%
47,776 $995,000
Q2 2020

Aug 13, 2020

BUY
$15.49 - $23.51 $139,255 - $211,354
8,990 Added 19.0%
56,299 $985,000
Q1 2020

May 06, 2020

BUY
$13.89 - $25.45 $24,251 - $44,435
1,746 Added 3.83%
47,309 $773,000
Q4 2019

Feb 05, 2020

BUY
$10.7 - $22.24 $10,090 - $20,972
943 Added 2.11%
45,563 $938,000
Q3 2019

Oct 23, 2019

BUY
$10.16 - $13.28 $7,172 - $9,375
706 Added 1.61%
44,620 $512,000
Q2 2019

Aug 14, 2019

BUY
$10.62 - $16.59 $57,687 - $90,116
5,432 Added 14.12%
43,914 $577,000
Q1 2019

May 01, 2019

SELL
$13.58 - $18.72 $7,278 - $10,033
-536 Reduced 1.37%
38,482 $583,000
Q4 2018

Jan 31, 2019

BUY
$14.78 - $19.68 $184,410 - $245,547
12,477 Added 47.01%
39,018 $670,000
Q3 2018

Nov 07, 2018

SELL
$14.16 - $24.3 $25,488 - $43,740
-1,800 Reduced 6.35%
26,541 $391,000
Q2 2018

Aug 06, 2018

BUY
$21.79 - $28.29 $63,539 - $82,493
2,916 Added 11.47%
28,341 $676,000
Q1 2018

May 02, 2018

BUY
$18.15 - $29.21 $4,392 - $7,068
242 Added 0.96%
25,425 $650,000
Q4 2017

Feb 09, 2018

SELL
$9.3 - $19.14 $22,785 - $46,893
-2,450 Reduced 8.87%
25,183 $465,000
Q3 2017

Nov 06, 2017

BUY
$9.15 - $11.97 $252,841 - $330,767
27,633
27,633 $290,000

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.1B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.